Table 3.
OS markers in the study groups: baseline and after six months.
| Parameters | EG1000 (n = 37) |
EG500 (n = 32) |
Placebo (n = 28) |
|||
|---|---|---|---|---|---|---|
| Baseline | Six months | Baseline | Six months | Baseline | Six months | |
| LPO (µmol/L) | 0.230 ± 0.08 | 0.212 ± 0.04 | 0.236 ± 0.09 | 0.229 ± 0.06 | 0.219 ± 0.07 | 0.282 ± 0.07 * |
| 8-Iso (pg/mL) | 60 ± 25 | 45 ± 27 | 56 ± 29 | 53 ± 38 | 61 ± 24 | 76 ± 35 † |
| GPx (UI/L) | 7181 ± 3794 | 8362 ± 2910 | 8219 ± 3616 | 8926 ± 3010 | 7635 ± 2988 | 7329 ± 3049 |
| Cat (×104 UI/gHb) | 3.0 ± 1 | 2.9 ± 1 | 2.9 ± 1 | 2.7 ± 1 | 2.9 ± 1 | 2.3 ± 1 |
| TAC (µmol/L) | 1003 ± 247 | 1225 ± 249 * | 1016 ± 216 | 1014 ± 269 | 1004 ± 202 | 993 ± 217 |
| SOD (Ul/L) | 167 ± 15 | 173 ± 12 | 172 ± 16 | 178 ± 10 | 171 ± 15 | 167 ± 10 † |
| SOD/GPx ratio | 0.030 ± 0.01 | 0.023 ± 0.01 | 0.027 ± 0.01 | 0.026 ± 0.01 | 0.026 ± 0.01 | 0.023 ± 0.01 |
| GAP | 283 ± 242 | 434 ± 234 ‡ | 288 ± 221 | 202 ± 284 | 276 ± 175 | 205 ± 229 |
| OSS | 2.5 ± 1 | 1.3 ± 1 | 2.0 ± 1 | 1.7 ± 1 | 1.9 ± 1 | 2.8 ± 1 * |
LPO: lipoperoxides; 8-Iso: isoprostanes; GPx: glutathione peroxidase; Cat: catalase; TAC: total antioxidant capacity; SOD: superoxide dismutase; OSS: oxidative stress score. Data are presented as mean ± SD. ANOVA of repeated measures. Tukey test as post hoc, * p < 0.05 placebo vs. EG1000; † p < 0.05 placebo vs. (EG1000 and EG500); ‡ p < 0.05 EG1000 vs. (EG500 and placebo).